


up-to-date with a click!

[View this email in your browser](#)

IAS STATIN
NEWSLETTER



INTERNATIONAL
ATHEROSCLEROSIS
SOCIETY

A CURATED WEEKLY UPDATE OF ALL STATIN PUBLICATIONS

Update - March, 2021



Curated by Peter Lansberg,
a Dutch lipidologist and educator, and
reviewed by prof. Philip Barter, Past President of the
International Atherosclerosis Society.

The IAS Statin Newsletter will keep you up-to-date with all recent statin publications, using a curated approach to select relevant articles.

Statin publications March 2021

Add on treatments

1. **Malik A, Ramadan A, Vemuri Bet *al.* ω -3 Ethyl ester results in better cognitive function at 12 and 30 months than control in cognitively healthy subjects with coronary artery disease: a secondary analysis of a randomized clinical trial.** The American journal of clinical nutrition 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33675344>

2. Jo SH, Han SH, Kim SH *et al.* Cardiovascular effects of omega-3 fatty acids: Hope or hype? *Atherosclerosis* 2021; 322:15-23.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33706079>
3. Lee J, Egolum U, Parihar H *et al.* Effect of Ezetimibe Added to High-Intensity Statin Therapy on Low-Density Lipoprotein Cholesterol Levels: A Meta-Analysis. *Cardiology research* 2021; 12:98-108.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33738013>
4. Kanagalingam T, Lazarte J, Wong DKH, Hegele RA. Liver Injury Associated With Ezetimibe Monotherapy. *CJC Open* 2021; 3:195-197.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33644733>
5. Turgeon RD, Sedlak T. Use of Preventive Medications in Patients With Nonobstructive Coronary Artery Disease: Analysis of the PROMISE Trial. *CJC Open* 2021; 3:159-166.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33644729>
6. Hermann R, Gundlach K, Seiler D. Mechanistic Considerations About an Unexpected Ramipril Drug-Drug Interaction in the Development of a Triple Fixed-Dose Combination Product Containing Ramipril, Amlodipine, and Atorvastatin. *Clinical pharmacology in drug development* 2021.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33773093>
7. Huh KY, Lee SW, Lee SB *et al.* Pharmacokinetic Interaction Among Ezetimibe, Rosuvastatin, and Telmisartan. *Clinical pharmacology in drug development* 2021.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33647189>
8. Boppana SH, Syed HA, Antwi-Amoabeng D *et al.* Atorvastatin-Induced Necrotizing Myopathy and its Response to Combination Therapy. *Cureus* 2021; 13:e12957.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33659112>
9. Ruscica M, Ferri N, Santos R *et al.* Lipid Lowering Drugs: Present Status and Future Developments. *Curr Atheroscler Rep* 2021; 23:17.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33694108>
10. Bahiru E, Hsiao R, Phillipson D, Watson KE. Mechanisms and Treatment of Dyslipidemia in Diabetes. *Current cardiology reports* 2021; 23:26.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33655372>

11. Pulipati VP, Davidson MH. The clinical black, white, and gray lessons. Curr Opin Lipidol 2021; 32:151-156. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33651748>
12. Strandberg TE, Kivimäki M. Increased mortality risk associated with statins in the CORONADO study. Diabetes Metab 2021:101250. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33744398>
13. Silvano J, Marques N, Tavares I, Ferreira I. Severe L-asparaginase-induced Hypertriglyceridaemia Treated with Plasmapheresis. European journal of case reports in internal medicine 2021; 8:002342. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33768080>
14. Diaz R, Li QH, Bhatt D *et al.* Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial. Eur J Prev Cardiol 2021; 28:33-43. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33755145>
15. Nguyen H, Akamnonu I, Yang T. Bempedoic Acid: a cholesterol lowering agent with a novel mechanism of action. Expert Rev Clin Pharmacol 2021:1-7. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33691561>
16. Welty FK, Schulte F, Alfaddagh A *et al.* Regression of human coronary artery plaque is associated with a high ratio of (18-hydroxy-eicosapentaenoic acid + resolvin E1) to leukotriene B(4). FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2021; 35:e21448. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33749913>
17. Jia W, Bai T, Zeng J *et al.* Combined Administration of Metformin and Atorvastatin Attenuates Diabetic Cardiomyopathy by Inhibiting Inflammation, Apoptosis, and Oxidative Stress in Type 2 Diabetic Mice. Front Cell Dev Biol 2021; 9:634900. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33718370>
18. Huang YJ, Kao S, Kao L *et al.* Association Between Statin Use and Exacerbation of Chronic Obstructive Pulmonary Disease Among Patients Receiving Corticosteroids. International journal of chronic obstructive pulmonary disease 2021; 16:591-602. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33716501>
19. Sammour Y, DeZorzi C, Austin B *et al.* PCSK9 Inhibitors in Heart Transplant Patients: Safety, Efficacy, and Angiographic Correlates. J Card Fail 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33753241>

20. Yen CL, Fan PC, Lin MSet *al.* Fenofibrate Delays the Need for Dialysis and Reduces Cardiovascular Risk among Patients with Advanced CKD. J Clin Endocrinol Metab 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33677489>
21. Oh M, Kim H, Shin EWet *al.* Statin/ezetimibe combination therapy vs statin monotherapy for carotid atherosclerotic plaque inflammation. Medicine (Baltimore) 2021; 100:e25114. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33725908>
22. Kao YC, Chen TH, Liu CHet *al.* Similar major cardiovascular outcomes between pure statin and ezetimibe-statin in comparable intensity for type 2 diabetes with extremely atherosclerotic risks. Scientific reports 2021; 11:6697. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33758291>
23. Šatný M. Fixed-dose combination of rosuvastatin and ezetimibe. Vnitr Lek 2020; 66:513-517. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33740852>
24. Soška V. Early and concurrent therapy of dyslipidemia and hypertension: when to start it and how to maintain patient's good and long-term adherence? Vnitr Lek 2021; 67:37-40. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33752389>

Adherence

1. Qu J, Du J, Rao Cet *al.* Effect of a Smartphone-Based Intervention on Secondary Prevention Medication Prescriptions After Coronary Artery Bypass Graft Surgery: The MISSION-1 Randomized Controlled Trial. Am Heart J 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33689732>
2. Youens D, Doust J, Robinson S, Moorin R. Regularity and Continuity of GP Contacts and Use of Statins Amongst People at Risk of Cardiovascular Events. Journal of general internal medicine 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33655384>
3. Hernández-Muñoz JJ, Wong ES, Kamdar CR. Prevalence of statin utilization and adherence among privately insured subjects in the Commonwealth of Puerto Rico. Journal of managed care & specialty pharmacy 2021; 27:392-398. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33645248>
4. Rinehart SN, Collins C, Glover J, Rice WM. Evaluation of a pharmacist-driven medication adherence enhancement service. Journal of managed care &

specialty pharmacy 2021; 27:507-515.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33769859>

5. Brodney S, Valentine KD, Sepucha Ket *al.* Patient Preference Distribution for Use of Statin Therapy. JAMA network open 2021; 4:e210661.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33720368>
6. Alsuhbani A, Albogami Y, Diaby Vet *al.* Evaluation of statin discontinuation stratified by primary versus secondary prevention following bariatric surgery: a retrospective cohort study. Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery 2021.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33648887>
7. Soška V. Early and concurrent therapy of dyslipidemia and hypertension: when to start it and how to maintain patient's good and long-term adherence? Vnitr Lek 2021; 67:37-40.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33752389>

Atherosclerosis & Imaging

1. Kim BS, Chan N, Hsu Get *al.* Sex Differences in Coronary Arterial Calcification in Symptomatic Patients. Am J Cardiol 2021.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33757786>
2. Afshar M, Yazdan-Ashoori S, Engert JC, Thanassoulis G. Drugs for prevention and treatment of aortic stenosis: how close are we? Can J Cardiol 2021.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33677100>
3. Nicholls SJ, Nissen SE, Prati Fet *al.* Assessing the impact of PCSK9 inhibition on coronary plaque phenotype with optical coherence tomography: rationale and design of the randomized, placebo-controlled HUYGENS study. Cardiovascular diagnosis and therapy 2021; 11:120-129.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33708484>
4. Otake H, Tanimura K, Sugizaki Yet *al.* Effect of Alirocumab and Rosuvastatin or Rosuvastatin Alone on Lipid Core Plaque in Coronary Artery Disease Seen on Near-Infrared Spectroscopy Intravascular Ultrasound (ANTARES). Circ Rep 2019; 1:107-111.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33693121>
5. Welty FK, Schulte F, Alfaddagh Aet *al.* Regression of human coronary artery plaque is associated with a high ratio of (18-hydroxy-eicosapentaenoic acid + resolvin E1) to leukotriene B(4). FASEB journal : official publication of the

Federation of American Societies for Experimental Biology 2021;
35:e21448.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33749913>

6. **Yelshibayeva E, Dautov T, Rakhimzhanova Ret al.COMPUTED TOMOGRAPHY IN DETECTING FEATURES OF CORONARY ATHEROSCLEROSIS IN DIFFERENT ETHNIC GROUPS OF KAZAKHSTAN POPULATION.**Georgian medical news 2021:68-77.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33658412>
7. **Sammour Y, DeZorzi C, Austin BAet al.PCSK9 Inhibitors in Heart Transplant Patients: Safety, Efficacy, and Angiographic Correlates.**J Card Fail 2021.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33753241>
8. **Oh M, Kim H, Shin EWet al.Statin/ezetimibe combination therapy vs statin monotherapy for carotid atherosclerotic plaque inflammation.**Medicine (Baltimore) 2021; 100:e25114.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33725908>
9. **Moorman AJ, Dean LS, Yang E, Drezner JA.Cardiovascular Risk Assessment in the Older Athlete.**Sports Health 2021:19417381211004877.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33733939>

Atorvastatin/Rosuvastatin

1. **Liu P, Gao Q, Guan Let al.Atorvastatin attenuates surgery-induced BBB disruption and cognitive impairment partly by suppressing NF-κB pathway and NLRP3 inflammasome activation in aged mice.**Acta biochimica et biophysica Sinica 2021.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33674828>
2. **Alamer A, Te C, Fazel MT.Rosuvastatin Myotoxicity After Starting Canagliflozin Treatment.**Annals of internal medicine 2021; 174:431.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33721529>
3. **Brailovski E, Kim RB, Juurlink D.Rosuvastatin Myotoxicity After Starting Canagliflozin Treatment.**Annals of internal medicine 2021; 174:432.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33721527>
4. **Mamidi R, Devineni D, Sun Det al.Rosuvastatin Myotoxicity After Starting Canagliflozin Treatment.**Annals of internal medicine 2021; 174:431-432.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33721528>
5. **Du X, Li D, Wang Get al.Chemoprotective effect of atorvastatin against benzo(a)pyrene-induced lung cancer via the inhibition of oxidative stress**

and inflammatory parameters.Annals of translational medicine 2021;
9:355.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33708982>

6. Furtado RHM, Genestreti PR, Dalção TF *et al.* Association between Statin Therapy and Lower Incidence of Hyperglycemia in Patients Hospitalized with Acute Coronary Syndromes.Arquivos brasileiros de cardiologia 2021;
116:285-294.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33656078>
7. Nishikido T, Fayyad R, Melamed S, Ray KK. TRS2P and LDL-C alone or in combination for predicting absolute benefits from additional LDL-C lowering: Analysis from the TNT trial.Atherosclerosis 2021; 322:8-14.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33706084>
8. Ren G, Zhou Q, Lu M, Wang H. Rosuvastatin corrects oxidative stress and inflammation induced by LPS to attenuate cardiac injury by inhibiting the NLRP3/TLR4 pathway.Canadian journal of physiology and pharmacology 2021.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33641435>
9. Joseph P, Glynn R, Lonn E *et al.* Rosuvastatin for the prevention of venous thromboembolism: a pooled analysis of the HOPE-3 and JUPITER randomized controlled trials.Cardiovascular research 2021.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33705531>
10. Tiemann J, Lindenkamp C, Plümers R *et al.* Statins as a Therapeutic Approach for the Treatment of Pseudoxanthoma Elasticum Patients: Evaluation of the Spectrum Efficacy of Atorvastatin In Vitro.Cells 2021;
10.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33669724>
11. Kuba JO, Yu Y, Klauda JB. Estimating Localization of Various Statins within a POPC Bilayer.Chemistry and physics of lipids 2021:105074.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33676920>
12. Otake H, Tanimura K, Sugizaki Y *et al.* Effect of Alirocumab and Rosuvastatin or Rosuvastatin Alone on Lipid Core Plaque in Coronary Artery Disease Seen on Near-Infrared Spectroscopy Intravascular Ultrasound (ANTARES).Circ Rep 2019; 1:107-111.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33693121>
13. Shutta R, Nakatani D, Sakata Y *et al.* Hydrophilic vs. Lipophilic Statins in Diabetic Patients - Comparison of Long-Term Outcomes After Acute Myocardial Infarction.Circ Rep 2020; 2:280-287.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33693242>
14. Turgeon RD, Sedlak T. Use of Preventive Medications in Patients With Nonobstructive Coronary Artery Disease: Analysis of the PROMISE Trial.CJC

Open 2021; 3:159-

166.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33644729>

15. Hermann R, Gundlach K, Seiler D. Mechanistic Considerations About an Unexpected Ramipril Drug-Drug Interaction in the Development of a Triple Fixed-Dose Combination Product Containing Ramipril, Amlodipine, and Atorvastatin. Clinical pharmacology in drug development 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33773093>
16. Huh KY, Lee SW, Lee SB *et al.* Pharmacokinetic Interaction Among Ezetimibe, Rosuvastatin, and Telmisartan. Clinical pharmacology in drug development 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33647189>
17. Boppana SH, Syed HA, Antwi-Amoabeng Det *et al.* Atorvastatin-Induced Necrotizing Myopathy and its Response to Combination Therapy. Cureus 2021; 13:e12957. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33659112>
18. Silvano J, Marques N, Tavares I, Ferreira I. Severe L-asparaginase-induced Hypertriglyceridaemia Treated with Plasmapheresis. European journal of case reports in internal medicine 2021; 8:002342. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33768080>
19. Gopaul VS, Pieterman EJ, Princen HM *et al.* Effects of mineral oil administration on the pharmacokinetics, metabolism and pharmacodynamics of atorvastatin and pravastatin in mice and dogs. Eur J Pharm Sci 2021:105776. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33667667>
20. Iqbal R, Qureshi OS, Yousaf AM *et al.* Enhanced solubility and biopharmaceutical performance of atorvastatin and metformin via electrospun polyvinylpyrrolidone-hyaluronic acid composite nanoparticles. Eur J Pharm Sci 2021; 161:105817. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33757829>
21. Jia W, Bai T, Zeng Jet *et al.* Combined Administration of Metformin and Atorvastatin Attenuates Diabetic Cardiomyopathy by Inhibiting Inflammation, Apoptosis, and Oxidative Stress in Type 2 Diabetic Mice. Front Cell Dev Biol 2021; 9:634900. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33718370>
22. Michael L, Caspar M, Alexander Ket *et al.* Major Depressive Disorder (MDD) and Antidepressant Medication Are Overrepresented in High-Dose Statin

Treatment.Frontiers in medicine 2021;

8:608083.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33644093>

23. Lei HP, Qin M, Cai LY *et al.* UGT1A1 rs4148323 A Allele is Associated With Increased 2-Hydroxy Atorvastatin Formation and Higher Death Risk in Chinese Patients With Coronary Artery Disease.Frontiers in pharmacology 2021;
12:586973.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33762934>
24. Kwak SY, Park S, Kim H *et al.* Atorvastatin Inhibits Endothelial PAI-1-Mediated Monocyte Migration and Alleviates Radiation-Induced Enteropathy.Int J Mol Sci 2021; 22.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33673196>
25. Grune C, Zens C, Czapka A *et al.* Sustainable preparation of anti-inflammatory atorvastatin PLGA nanoparticles.Int J Pharm 2021:120404.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33647413>
26. Mueller AM, Liakoni E, Schneider C *et al.* The Risk of Muscular Events Among New Users of Hydrophilic and Lipophilic Statins: an Observational Cohort Study.Journal of general internal medicine 2021.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33751411>
27. Lee J, Hong EM, Jung JH *et al.* Atorvastatin Induces FXR and CYP7A1 Activation as a Result of the Sequential Action of PPAR γ /PGC-1 α /HNF-4 α in Hep3B Cells.Korean J Gastroenterol 2021.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33686046>
28. Mounier NM, Wahdan SA, Gad AM, Azab SS. Role of inflammatory, oxidative, and ER stress signaling in the neuroprotective effect of atorvastatin against doxorubicin-induced cognitive impairment in rats.Naunyn-Schmiedeberg's archives of pharmacology 2021.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33755739>
29. Climent E, Marco-Benedí V, Benaiges D *et al.* Impact of statin therapy on LDL and non-HDL cholesterol levels in subjects with heterozygous familial hypercholesterolaemia.Nutrition, metabolism, and cardiovascular diseases : NMCD 2021.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33744038>
30. van Boheemen L, Turk S, Beers-Tas M *et al.* Atorvastatin is unlikely to prevent rheumatoid arthritis in high risk individuals: results from the prematurely stopped STATins to Prevent Rheumatoid Arthritis (STAPRA) trial.RMD Open 2021;
7.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33685928>

31. Sharma T, Abohashrh M, Baig MH *et al.* Screening of drug databank against WT and mutant main protease of SARS-CoV-2: Towards finding potential compound for repurposing against COVID-19. Saudi journal of biological sciences 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33649700>
32. Kao YC, Chen TH, Liu CH *et al.* Similar major cardiovascular outcomes between pure statin and ezetimibe-statin in comparable intensity for type 2 diabetes with extremely atherosclerotic risks. Scientific reports 2021; 11:6697. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33758291>
33. Dikmen G, Uslu O. The application of qNMR for the determination of rosuvastatin in tablet form. Turk J Chem 2021; 45:132-142. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33679159>

Basic science

1. Liu P, Gao Q, Guan L *et al.* Atorvastatin attenuates surgery-induced BBB disruption and cognitive impairment partly by suppressing NF- κ B pathway and NLRP3 inflammasome activation in aged mice. Acta biochimica et biophysica Sinica 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33674828>
2. Ni X, Yang ZZ, Ye LQ *et al.* Establishment of an in vitro safety assessment model for lipid-lowering drugs using same-origin human pluripotent stem cell-derived cardiomyocytes and endothelial cells. Acta pharmacologica Sinica 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33686244>
3. Yazdani Ashtiani S, Ahmad Nasrollahi S, Naeimifar A *et al.* Preparation and Safety Evaluation of Topical Simvastatin Loaded NLCs for Vitiligo. Advanced pharmaceutical bulletin 2021; 11:104-110. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33747857>
4. Du X, Li D, Wang G *et al.* Chemoprotective effect of atorvastatin against benzo(a)pyrene-induced lung cancer via the inhibition of oxidative stress and inflammatory parameters. Annals of translational medicine 2021; 9:355. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33708982>
5. Dai B, Li X, Xu J *et al.* Synergistic effects of magnesium ions and simvastatin on attenuation of high-fat diet-induced bone loss. Bioact Mater 2021; 6:2511-2522. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33665494>
6. Rizo-Liendo A, Arberas-Jiménez I, Sifaoui I *et al.* The type 2 statins, cerivastatin, rosuvastatin and pitavastatin eliminate *Naegleria fowleri* at low concentrations and by induction of programmed cell death (PCD). Bioorganic

chemistry 2021;

110:104784.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33684715>

7. Ouahoud S, Jacobs RJ, Peppelenbosch MP *et al.* Kinome-wide analysis of the effect of statins in colorectal cancer. Br J Cancer 2021.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33742146>
8. Ren G, Zhou Q, Lu M, Wang H. Rosuvastatin corrects oxidative stress and inflammation induced by LPS to attenuate cardiac injury by inhibiting the NLRP3/TLR4 pathway. Canadian journal of physiology and pharmacology 2021.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33641435>
9. Ikonopoulou MP, Lopez-Mancheño Y, Novelle M *et al.* LXR stimulates a metabolic switch and reveals cholesterol homeostasis as a statin target in Tasmanian devil facial tumor disease. Cell Rep 2021; **34:108851.**<http://www.ncbi.nlm.nih.gov/pubmed/?term=33730574>
10. Kuba JO, Yu Y, Klauda JB. Estimating Localization of Various Statins within a POPC Bilayer. Chemistry and physics of lipids 2021:105074.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33676920>
11. Kessinger CW, Qi G, Hassan MZ *et al.* Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Imaging Predicts Vein Wall Scarring and Statin Benefit in Murine Venous Thrombosis. Circulation. Cardiovascular imaging 2021:Circimaging120011898.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33724049>
12. Zhu L, Liu F, Hao Q *et al.* Dietary Geranylgeranyl Pyrophosphate Counteracts the Benefits of Statin Therapy in Experimental Pulmonary Hypertension. Circulation 2021.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33660517>
13. Cruz R, Moraschini V, Calasans-Maia M *et al.* Clinical efficacy of simvastatin gel combined with polypropylene membrane on the healing of extraction sockets: a triple-blind, randomized clinical trial. Clinical oral implants research 2021.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33715258>
14. Iqbal R, Qureshi OS, Yousaf A *et al.* Enhanced solubility and biopharmaceutical performance of atorvastatin and metformin via electrospun polyvinylpyrrolidone-hyaluronic acid composite nanoparticles. Eur J Pharm Sci 2021; **161:105817.**<http://www.ncbi.nlm.nih.gov/pubmed/?term=33757829>

15. Welty FK, Schulte F, Alfaddagh A *et al.* Regression of human coronary artery plaque is associated with a high ratio of (18-hydroxy-eicosapentaenoic acid + resolvin E1) to leukotriene B(4). FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2021; 35:e21448. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33749913>
16. Menze ET, Ezzat H, Shawky S *et al.* Simvastatin mitigates depressive-like behavior in ovariectomized rats: Possible role of NLRP3 inflammasome and estrogen receptors' modulation. Int Immunopharmacol 2021; 95:107582. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33774267>
17. Kwak SY, Park S, Kim H *et al.* Atorvastatin Inhibits Endothelial PAI-1-Mediated Monocyte Migration and Alleviates Radiation-Induced Enteropathy. Int J Mol Sci 2021; 22. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33673196>
18. Wang H, Wang T, Zhang Z *et al.* Simvastatin inhibits oral squamous cell carcinoma by targeting TMEM16A Ca(2+)-activated chloride channel. Journal of cancer research and clinical oncology 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33755783>
19. Bornfeldt KE. Triglyceride lowering by omega-3 fatty acids: a mechanism mediated by N-acyl taurines. J Clin Invest 2021; 131. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33720044>
20. Li Y, Zhang YX, Ning D *et al.* Simvastatin inhibits POVPC-mediated induction of endothelial to mesenchymal cell transition. Journal of lipid research 2021:100066. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33711324>
21. Lima Cunha D, Richardson R, Tracey-White D *et al.* REP1-deficiency causes systemic dysfunction of lipid metabolism and oxidative stress in choroideremia. JCI insight 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33755601>
22. Lee J, Hong EM, Jung JH *et al.* Atorvastatin Induces FXR and CYP7A1 Activation as a Result of the Sequential Action of PPAR γ /PGC-1 α /HNF-4 α in Hep3B Cells. Korean J Gastroenterol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33686046>
23. Yuvaraj S, Ramprasath T, Saravanan B *et al.* Chrysin attenuates high-fat-diet-induced myocardial oxidative stress via upregulating eNOS and Nrf2 target genes in rats. Molecular and cellular biochemistry 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33677805>

24. Chen N, Ren R, Wei X *et al.* Thermoresponsive Hydrogel-Based Local Delivery of Simvastatin for the Treatment of Periodontitis. Molecular pharmaceutics 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33754729>
25. Mounier NM, Wahdan SA, Gad AM, Azab SS. Role of inflammatory, oxidative, and ER stress signaling in the neuroprotective effect of atorvastatin against doxorubicin-induced cognitive impairment in rats. Naunyn-Schmiedeberg's archives of pharmacology 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33755739>
26. Du RW, Bu WG. Simvastatin Prevents Neurodegeneration in the MPTP Mouse Model of Parkinson's Disease via Inhibition of A1 Reactive Astrocytes. Neuroimmunomodulation 2021;1-8. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33735898>
27. Fan Q, Gong T, Zheng C *et al.* Statins repress hedgehog signaling in medulloblastoma with no bone toxicities. Oncogene 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33649536>
28. van Gemert Y, Kozijn AE, Pouwer M *et al.* Novel high-intensive cholesterol-lowering therapies do not ameliorate knee OA development in humanized dyslipidemic mice. Osteoarthritis and cartilage 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33722697>
29. Cerda A, Bortolin RH, Manriquez V *et al.* Effect of statins on lipid metabolism-related microRNA expression in HepG2 cells. Pharmacological reports : PR 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33721286>
30. Nenna A, Nappi F, Larobina D *et al.* Polymers and Nanoparticles for Statin Delivery: Current Use and Future Perspectives in Cardiovascular Disease. Polymers (Basel) 2021; 13. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33652927>
31. Zhong S, Li L, Liang N *et al.* Acetaldehyde Dehydrogenase 2 regulates HMG-CoA reductase stability and cholesterol synthesis in the liver. Redox biology 2021; 41:101919. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33740503>
32. Yan L, Jiaqiong L, Yue G *et al.* Atorvastatin protects against contrast-induced acute kidney injury via upregulation of endogenous hydrogen sulfide. Ren Fail 2020; 42:270-281. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33685337>

33. Li HX, Liang XY, Wu JH *et al.* Simvastatin attenuates acute lung injury by activation of A2B adenosine receptor. Toxicology and applied pharmacology 2021;115460. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33774062>
34. Barreto A, Santos J, Amorim MJB, Maria VL. Polystyrene Nanoplastics Can Alter the Toxicological Effects of Simvastatin on *Danio rerio*. Toxics 2021; 9. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33652851>
35. Dikmen G, Uslu O. The application of qNMR for the determination of rosuvastatin in tablet form. Turk J Chem 2021; 45:132-142. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33679159>

Cancer

1. Du X, Li D, Wang G *et al.* Chemoprotective effect of atorvastatin against benzo(a)pyrene-induced lung cancer via the inhibition of oxidative stress and inflammatory parameters. Annals of translational medicine 2021; 9:355. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33708982>
2. Keit E, Coutu B, Zhen W *et al.* Systemic inflammation is associated with inferior disease control and survival in stage III non-small cell lung cancer. Annals of translational medicine 2021; 9:227. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33708854>
3. Ouahoud S, Jacobs RJ, Peppelenbosch M *et al.* Kinome-wide analysis of the effect of statins in colorectal cancer. Br J Cancer 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33742146>
4. Yulian ED, Siregar NC, Bajuadji. Combination of Simvastatin and FAC Improves Response to Neoadjuvant Chemotherapy in Advanced Local Breast Cancer. Cancer research and treatment : official journal of Korean Cancer Association 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33705623>
5. Li L, Cui N, Hao T *et al.* Statins use and the prognosis of colorectal cancer: a meta-analysis. Clin Res Hepatol Gastroenterol 2021; 45:101588. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33662632>
6. Silvano J, Marques N, Tavares I, Ferreira I. Severe L-asparaginase-induced Hypertriglyceridaemia Treated with Plasmapheresis. European journal of case reports in internal medicine 2021; 8:002342. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33768080>

7. Liebow M, Larson MC, Thompson CA *et al.* Aspirin and other nonsteroidal anti-inflammatory drugs, statins and risk of non-Hodgkin lymphoma. International journal of cancer. Journal international du cancer 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33644854>
8. Wang H, Wang T, Zhang Z *et al.* Simvastatin inhibits oral squamous cell carcinoma by targeting TMEM16A Ca(2+)-activated chloride channel. Journal of cancer research and clinical oncology 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33755783>
9. Fan Q, Gong T, Zheng C *et al.* Statins repress hedgehog signaling in medulloblastoma with no bone toxicities. Oncogene 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33649536>

Children

1. Donovan GK, Wilson DP. Ethical Dilemmas in Pediatric Lipidology. In: Endotext. Edited by: Feingold KR, Anawalt B, Boyce A *et al.* South Dartmouth (MA): MDText.com, Inc. Copyright © 2000-2021, MDText.com, Inc.; 2000.
2. Hennig M, Brandt A, Bautembach-Minkowska J *et al.* When do paediatric patients with familial hypercholesterolemia need statin therapy?(). J Mother Child 2021; 21:43-50. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33751874>
3. Baliga MM, Klawitter J, Christians U *et al.* Metabolic profiling in children and young adults with autosomal dominant polycystic kidney disease. Scientific reports 2021; 11:6629. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33758231>

Cost-effectiveness

1. Saeed A, Saeed F, Saeed H *et al.* Access to Essential Cardiovascular Medicines in Pakistan: A National Survey on the Availability, Price, and Affordability, Using WHO/HAI Methodology. Frontiers in pharmacology 2020; 11:595008. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33708114>
2. Boettiger DC, Newall AT, Phillips A *et al.* Cost-effectiveness of statins for primary prevention of atherosclerotic cardiovascular disease among people living with HIV in the United States. Journal of the International AIDS Society 2021; 24:e25690. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33749164>

3. Ohm J, Skoglund PH, Häbel *Het al.* Association of Socioeconomic Status With Risk Factor Target Achievements and Use of Secondary Prevention After Myocardial Infarction. JAMA network open 2021; 4:e211129. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33688966>

CVD

1. Qu J, Du J, Rao *Cet al.* Effect of a Smartphone-Based Intervention on Secondary Prevention Medication Prescriptions After Coronary Artery Bypass Graft Surgery: The MISSION-1 Randomized Controlled Trial. Am Heart J 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33689732>
2. Shutta R, Nakatani D, Sakata *Yet al.* Hydrophilic vs. Lipophilic Statins in Diabetic Patients - Comparison of Long-Term Outcomes After Acute Myocardial Infarction. Circ Rep 2020; 2:280-287. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33693242>
3. Turgeon RD, Sedlak T. Use of Preventive Medications in Patients With Nonobstructive Coronary Artery Disease: Analysis of the PROMISE Trial. CJC Open 2021; 3:159-166. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33644729>
4. Terman SW, Aubert CE, Hill *CEet al.* Cardiovascular disease risk, awareness, and treatment in people with epilepsy. Epilepsy & behavior : E&B 2021; 117:107878. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33690068>
5. Diaz R, Li QH, Bhatt *DLet al.* Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial. Eur J Prev Cardiol 2021; 28:33-43. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33755145>
6. Lu T, Yang X, Cai *Yet al.* Prestroke Statins Improve Prognosis of Atrial Fibrillation-Associated Stroke through Increasing Suppressor of Cytokine Signaling-3 Levels. European neurology 2021:1-7. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33684912>
7. Arnesen KE, Phung AV, Randsborg *Ket al.* Risk of Recurrent Coronary Events in Patients With Familial Hypercholesterolemia; A 10-Years Prospective Study. Frontiers in pharmacology 2020; 11:560958. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33737874>
8. Schiele F, Quignot N, Khachatryan *Aet al.* Clinical impact and room for improvement of intensity and adherence to lipid lowering therapy: Five years of clinical follow-up from 164,565 post-myocardial infarction

patients.Int J

Cardiol 2021.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33705845>

9. Johannesen CDL, Mortensen MB, Langsted A, Nordestgaard BG. Apolipoprotein B and Non-HDL Cholesterol Better Reflect Residual Risk Than LDL Cholesterol in Statin-Treated Patients. J Am Coll Cardiol 2021; 77:1439-1450. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33736827>
10. Nagayama D, Saiki A, Watanabe Y *et al.* Prevention of Cardiovascular Events with Pitavastatin is Associated with Increased Serum Lipoprotein Lipase Mass Level: Subgroup Analysis of the TOHO-LIP. J Atheroscler Thromb 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33642441>
11. Sammour Y, DeZorzi C, Austin BA *et al.* PCSK9 Inhibitors in Heart Transplant Patients: Safety, Efficacy, and Angiographic Correlates. J Card Fail 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33753241>
12. Nomani H, Mohammadpour AH, Reiner Ž *et al.* Statin Therapy in Post-Operative Atrial Fibrillation: Focus on the Anti-Inflammatory Effects. J Cardiovasc Dev Dis 2021; 8. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33652637>
13. Fiedler L, Hallsson L, Tscharré M *et al.* Upstream Statin Therapy and Long-Term Recurrence of Atrial Fibrillation after Cardioversion: A Propensity-Matched Analysis. Journal of clinical medicine 2021; 10. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33671264>
14. Chhibber A, Hansen S, Biskupiak J. Statin use and mortality in rheumatoid arthritis: an incident user cohort study. Journal of managed care & specialty pharmacy 2021; 27:296-305. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33645241>
15. Tara S, Yamamoto T, Sakai S *et al.* Clinical characteristics, secondary prevention goal attainment, and outcomes of patients with recurrent acute coronary syndrome. J Nippon Med Sch 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33692293>
16. Giannis D, Barish MA, Goldin M *et al.* Incidence of Venous Thromboembolism and Mortality in Patients with Initial Presentation of COVID-19. Journal of thrombosis and thrombolysis 2021:1-5. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33665766>
17. Ohm J, Skoglund PH, Häbel H *et al.* Association of Socioeconomic Status With Risk Factor Target Achievements and Use of Secondary Prevention After

Myocardial Infarction.*JAMA network open* 2021;
4:e211129.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33688966>

18. Allan S, Olaiya R, Burhan R. Reviewing the use and quality of machine learning in developing clinical prediction models for cardiovascular disease. *Postgraduate medical journal* 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33692158>
19. Huber D, Wikén C, Henriksson Ret *al.* Author Correction: Statin treatment after acute coronary syndrome: Adherence and reasons for non-adherence in a randomized controlled intervention trial. *Scientific reports* 2021; 11:6454. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33723289>

Endothelium/inflammation

1. Keit E, Coutu B, Zhen Wet *al.* Systemic inflammation is associated with inferior disease control and survival in stage III non-small cell lung cancer. *Annals of translational medicine* 2021; 9:227. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33708854>
2. Kauerova S, Bartuskova H, Muffova Bet *al.* Statins Directly Influence the Polarization of Adipose Tissue Macrophages: A Role in Chronic Inflammation. *Biomedicines* 2021; 9. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33669779>
3. Ren G, Zhou Q, Lu M, Wang H. Rosuvastatin corrects oxidative stress and inflammation induced by LPS to attenuate cardiac injury by inhibiting the NLRP3/TLR4 pathway. *Canadian journal of physiology and pharmacology* 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33641435>
4. Lecumberri E, Ruiz-Carmona C, Mateos Eet *al.* Prognostic Value of Inflammatory Biomarkers in 5-Year Survival After Endovascular Repair of Abdominal Aortic Aneurysms in a Predominantly Male Cohort: Implications for Practice. *World journal of surgery* 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33721070>

Ethnicity

1. Valladales-Restrepo LF, Medina-Morales DA, Giraldo-Giraldo C, Machado-Alba JE. Prescription of statins and pharmacokinetic interactions in Colombian patients. *Expert Opin Drug Metab Toxicol* 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33759676>

2. Lei HP, Qin M, Cai LY *et al.* UGT1A1 rs4148323 A Allele is Associated With Increased 2-Hydroxy Atorvastatin Formation and Higher Death Risk in Chinese Patients With Coronary Artery Disease. Frontiers in pharmacology 2021; 12:586973. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33762934>
3. Cohen H, Durst R, Elis A *et al.* [TREATMENT OF HOMOZYGOTES OF FAMILIAL HYPERCHOLESTEROLEMIA: RECOMMENDATIONS OF THE ISRAELI SOCIETY OF ATHEROSCLEROSIS]. Harefuah 2021; 160:170-174. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33749180>
4. Sarfo FS, Adamu S, Obese V *et al.* Atherosclerotic event risk and risk reduction therapies among Ghanaian hemorrhagic stroke survivors. J Neurol Sci 2021; 424:117389. <http://www.ncbi.nlm.nih.gov/pubmed/?term=3377340>

FH

1. Petrov I, Postadzhiyan A, Vasilev D *et al.* Familial Hypercholesterolemia Identification Algorithm in Patients with Acute Cardiovascular Events in A Large Hospital Electronic Database in Bulgaria: A Call for Implementation. Adv Ther 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33754300>
2. Arnesen KE, Phung AV, Randsborg K *et al.* Risk of Recurrent Coronary Events in Patients With Familial Hypercholesterolemia; A 10-Years Prospective Study. Frontiers in pharmacology 2020; 11:560958. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33737874>
3. Cohen H, Durst R, Elis A *et al.* [TREATMENT OF HOMOZYGOTES OF FAMILIAL HYPERCHOLESTEROLEMIA: RECOMMENDATIONS OF THE ISRAELI SOCIETY OF ATHEROSCLEROSIS]. Harefuah 2021; 160:170-174. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33749180>
4. Rosenson RS. Existing and emerging therapies for the treatment of familial hypercholesterolemia. Journal of lipid research 2021:100060. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33716107>
5. Climent E, Marco-Benedí V, Benaiges D *et al.* Impact of statin therapy on LDL and non-HDL cholesterol levels in subjects with heterozygous familial hypercholesterolaemia. Nutrition, metabolism, and cardiovascular diseases : NMCD 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33744038>

Generics

1. Manasirisuk P, Chainirun N, Tiamkao Set *al.* Efficacy of Generic Atorvastatin in a Real-World Setting. Clinical pharmacology : advances and applications 2021; 13:45-51. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33707972>

Genetics

1. Tian Y, Wang J, Liu Yet *al.* MassARRAY multigene screening combined with LDL-C and sdLDL-C detection for more favorable outcomes in type 2 diabetes mellitus therapy. BMC medical genomics 2021; 14:83. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33731122>
2. Lei HP, Qin M, Cai LY *et al.* UGT1A1 rs4148323 A Allele is Associated With Increased 2-Hydroxy Atorvastatin Formation and Higher Death Risk in Chinese Patients With Coronary Artery Disease. Frontiers in pharmacology 2021; 12:586973. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33762934>
3. Sun M, Lemaçon A, Legault MA *et al.* Genetic meta-analysis of cancer diagnosis following statin use identifies new associations and implicates human leukocyte antigen (HLA) in women. Pharmacogenomics J 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33649522>

Guidelines

1. Lindsley J. Guideline recommendations, clinical trial data, and new and emerging therapies. The American journal of managed care 2021; 27:S70-S75. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33710846>
2. Koskinas KC, Gencer B, Nanchen Det *al.* Eligibility for PCSK9 inhibitors based on the 2019 ESC/EAS and 2018 ACC/AHA guidelines. Eur J Prev Cardiol 2021; 28:59-65. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33755142>
3. Cohen H, Durst R, Elis A *et al.* [TREATMENT OF HOMOZYGOTES OF FAMILIAL HYPERCHOLESTEROLEMIA: RECOMMENDATIONS OF THE ISRAELI SOCIETY OF ATHEROSCLEROSIS]. Harefuah 2021; 160:170-174. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33749180>
4. Masson W, Rossi E, Alvarado R *Net al.* Rheumatoid Arthritis, Statin Indication and Lipid Goals: Analysis According to Different

Recommendations.Reumatologia

clinica 2021.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33745866>

LDL- related parameters

1. Nishikido T, Fayyad R, Melamed S, Ray KK. TRS2P and LDL-C alone or in combination for predicting absolute benefits from additional LDL-C lowering: Analysis from the TNT trial. Atherosclerosis 2021; 322:8-14. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33706084>
2. Lee J, Egolum U, Parihar Het *al.* Effect of Ezetimibe Added to High-Intensity Statin Therapy on Low-Density Lipoprotein Cholesterol Levels: A Meta-Analysis. Cardiology research 2021; 12:98-108. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33738013>
3. Singh P, Goncalves I, Tengryd Cet *al.* Correction to: Reduced oxidized LDL in T2D plaques is associated with a greater statin usage but not with future cardiovascular events. Cardiovascular diabetology 2021; 20:61. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33711997>
4. Tiemann J, Lindenkamp C, Plümers Ret *al.* Statins as a Therapeutic Approach for the Treatment of Pseudoxanthoma Elasticum Patients: Evaluation of the Spectrum Efficacy of Atorvastatin In Vitro. Cells 2021; 10. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33669724>
5. Farooque U, Lohano AK, Dahri Qet *al.* The Pattern of Dyslipidemia in Chronic Liver Disease Patients. Cureus 2021; 13:e13259. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33728198>
6. Schiele F, Quignot N, Khachatryan Aet *al.* Clinical impact and room for improvement of intensity and adherence to lipid lowering therapy: Five years of clinical follow-up from 164,565 post-myocardial infarction patients. Int J Cardiol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33705845>
7. Johannesen CDL, Mortensen MB, Langsted A, Nordestgaard BG. Apolipoprotein B and Non-HDL Cholesterol Better Reflect Residual Risk Than LDL Cholesterol in Statin-Treated Patients. J Am Coll Cardiol 2021; 77:1439-1450. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33736827>
8. Nagayama D, Saiki A, Watanabe Yet *al.* Prevention of Cardiovascular Events with Pitavastatin is Associated with Increased Serum Lipoprotein Lipase

**Mass Level: Subgroup Analysis of the TOHO-LIP.J Atheroscler
Thromb 2021.**<http://www.ncbi.nlm.nih.gov/pubmed/?term=33642441>

9. Sarfo FS, Adamu S, Obese Vet *al.*Atherosclerotic event risk and risk reduction therapies among Ghanaian hemorrhagic stroke survivors.*J Neurol Sci* 2021;
424:117389.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33773409>
10. Emmons RP, Hastain NV, Miano TA, Schafer JJ.Patients Living With HIV Are Less Likely to Receive Appropriate Statin Therapy for Cardiovascular Disease Risk Reduction.*Journal of pharmacy practice* 2021:897190021999790.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33678059>
11. Ohm J, Skoglund PH, Häbel Het *al.*Association of Socioeconomic Status With Risk Factor Target Achievements and Use of Secondary Prevention After Myocardial Infarction.*JAMA network open* 2021;
4:e211129.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33688966>
12. Climent E, Marco-Benedí V, Benaiges Det *al.*Impact of statin therapy on LDL and non-HDL cholesterol levels in subjects with heterozygous familial hypercholesterolaemia.*Nutrition, metabolism, and cardiovascular diseases : NMCD* 2021.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33744038>
13. Phoon IKY, Koh YLE, Guo Xet *al.*Compatibility between an overnight fasting and random cholesterol tests in Asians.*Scientific reports* 2021;
11:6478.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33742059>
14. Šatný M.Fixed-dose combination of rosuvastatin and ezetimibe.*Vnitr Lek* 2020; 66:513-
517.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33740852>

Lifestyle

1. Zhu L, Liu F, Hao Qet *al.*Dietary Geranylgeranyl Pyrophosphate Counteracts the Benefits of Statin Therapy in Experimental Pulmonary Hypertension.*Circulation* 2021.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33660517>

Meta-analyses

1. Lee J, Egolum U, Parihar Het *al.*Effect of Ezetimibe Added to High-Intensity Statin Therapy on Low-Density Lipoprotein Cholesterol Levels: A Meta-

Analysis.Cardiology research 2021; 12:98-108.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33738013>

2. Li L, Cui N, Hao Tet *al.* Statins use and the prognosis of colorectal cancer: a meta-analysis.Clin Res Hepatol Gastroenterol 2021; 45:101588.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33662632>
3. Wright RS, Ray KK, Raal FJet *al.* Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis.J Am Coll Cardiol 2021; 77:1182-1193.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33663735>
4. Masson W, Lobo M, Masson Get *al.* Statin use in patients with elevated serum hepatic transaminases at baseline: A meta-analysis.Nutrition, metabolism, and cardiovascular diseases : NMCD 2021.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33715945>
5. Sun M, Lemaçon A, Legault MAet *al.* Genetic meta-analysis of cancer diagnosis following statin use identifies new associations and implicates human leukocyte antigen (HLA) in women.Pharmacogenomics J 2021.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33649522>

Metabolic Syndrome - Diabetes

1. Tian Y, Wang J, Liu Yet *al.* MassARRAY multigene screening combined with LDL-C and sdLDL-C detection for more favorable outcomes in type 2 diabetes mellitus therapy.BMC medical genomics 2021; 14:83.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33731122>
2. Ahmad MI, Shapiro MD. Preventing Diabetes and Atherosclerosis in the Cardiometabolic Syndrome.Curr Atheroscler Rep 2021; 23:16.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33686460>
3. Bahiru E, Hsiao R, Phillipson D, Watson KE. Mechanisms and Treatment of Dyslipidemia in Diabetes.Current cardiology reports 2021; 23:26.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33655372>
4. Jia W, Bai T, Zeng Jet *al.* Combined Administration of Metformin and Atorvastatin Attenuates Diabetic Cardiomyopathy by Inhibiting Inflammation, Apoptosis, and Oxidative Stress in Type 2 Diabetic Mice.Front Cell Dev Biol 2021; 9:634900.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33718370>

5. Vega GL, Wang J, Grundy SM. Utility of metabolic syndrome as a risk enhancing factor in decision of statin use. J Clin Lipidol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33663990>
6. Hernández-Muñoz JJ, Wong ES, Kamdar CR. Prevalence of statin utilization and adherence among privately insured subjects in the Commonwealth of Puerto Rico. Journal of managed care & specialty pharmacy 2021; 27:392-398. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33645248>
7. Ciardullo S, Perseghin G. Statin use is associated with lower prevalence of advanced liver fibrosis in patients with type 2 diabetes. Metabolism 2021:154752. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33716004>
8. Kao YC, Chen TH, Liu CH *et al.* Similar major cardiovascular outcomes between pure statin and ezetimibe-statin in comparable intensity for type 2 diabetes with extremely atherosclerotic risks. Scientific reports 2021; 11:6697. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33758291>

New Treatments

1. Patel J. Managed care pharmacist updates for proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. The American journal of managed care 2021; 27:S76-S82. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33710847>
2. Shaw PB. Hyperlipidemia: effective disease management with a focus on PCSK9 inhibitors. The American journal of managed care 2021; 27:S63-S69. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33710845>
3. Nicholls SJ, Nissen SE, Prati F *et al.* Assessing the impact of PCSK9 inhibition on coronary plaque phenotype with optical coherence tomography: rationale and design of the randomized, placebo-controlled HUYGENS study. Cardiovascular diagnosis and therapy 2021; 11:120-129. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33708484>
4. Otake H, Tanimura K, Sugizaki Y *et al.* Effect of Alirocumab and Rosuvastatin or Rosuvastatin Alone on Lipid Core Plaque in Coronary Artery Disease Seen on Near-Infrared Spectroscopy Intravascular Ultrasound (ANTARES). Circ Rep 2019; 1:107-111. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33693121>
5. Mylonas KS, Iliopoulos D, Nikiteas N, Schizas D. Looking for the Achilles heel of atheromatosis: could it be

immunotherapy?Immunotherapy 2021.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33757293>

6. **Nurmohamed NS, Navar AM, Kastelein JJP.** New and Emerging Therapies for Reduction of LDL-Cholesterol and Apolipoprotein B: JACC Focus Seminar 1/4. J Am Coll Cardiol 2021; 77:1564-1575.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33766264>
7. **Wright RS, Ray KK, Raal FJ et al.** Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis. J Am Coll Cardiol 2021; 77:1182-1193.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33663735>
8. **Sammour Y, DeZorzi C, Austin BA et al.** PCSK9 Inhibitors in Heart Transplant Patients: Safety, Efficacy, and Angiographic Correlates. J Card Fail 2021.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33753241>
9. **Rosenson RS.** Existing and emerging therapies for the treatment of familial hypercholesterolemia. Journal of lipid research 2021:100060.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33716107>
10. **van Gemert Y, Kozijn AE, Pouwer MG et al.** Novel high-intensive cholesterol-lowering therapies do not ameliorate knee OA development in humanized dyslipidemic mice. Osteoarthritis and cartilage 2021.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33722697>

Other

1. **Virtanen A, Haukka J, Harju M, Loukovaara S.** Statin use and the reoperation rates in glaucoma filtration surgery - population-based cohort study. Acta ophthalmologica 2021.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33755323>
2. **Malik A, Ramadan A, Vemuri B et al.** ω -3 Ethyl ester results in better cognitive function at 12 and 30 months than control in cognitively healthy subjects with coronary artery disease: a secondary analysis of a randomized clinical trial. The American journal of clinical nutrition 2021.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33675344>
3. **Chacko SR, DeJoy R, 3rd, Lo KB et al.** Association of pre-admission statin use with reduced in-hospital mortality in COVID-19. Am J Med Sci 2021.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33667433>

4. Farooque U, Lohano AK, Dahri Qet *al*.The Pattern of Dyslipidemia in Chronic Liver Disease Patients.Cureus 2021;
13:e13259.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33728198>
5. Nicholson CJ, Wooster L, Sigursslid HHet *al*.Estimating risk of mechanical ventilation and in-hospital mortality among adult COVID-19 patients admitted to Mass General Brigham: The VICE and DICE scores.EClinicalMedicine 2021;
33:100765.<http://www.ncbi.nlm.nih.gov/pubmed/?term=3365204>
6. Gopaul VS, Pieterman EJ, Princen HMGet *al*.Effects of mineral oil administration on the pharmacokinetics, metabolism and pharmacodynamics of atorvastatin and pravastatin in mice and dogs.Eur J Pharm Sci 2021:105776.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33667667>
7. Ying Q, Chan DC, Watts GF.New Insights Into the Regulation of Lipoprotein Metabolism by PCSK9: Lessons From Stable Isotope Tracer Studies in Human Subjects.Front Physiol 2021;
12:603910.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33643062>
8. Stone NJ, Lloyd-Jones D.Tracking Residual Risk: Time for a Change?J Am Coll Cardiol 2021; 77:1451-1453.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33736828>
9. Cho HW, Song IA, Oh TK.Prior Statin Therapy and Mortality After Extracorporeal Membrane Oxygenation Therapy: A Retrospective, Population-Based, Cohort Study.Journal of cardiothoracic and vascular anesthesia 2021.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33715948>
10. Lohia P, Kapur S, Benjaram S, Mir T.Association between antecedent statin use and severe disease outcomes in COVID-19: A retrospective study with propensity score matching.J Clin Lipidol 2021.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33726984>
11. Boettiger DC, Newall AT, Phillips Aet *al*.Cost-effectiveness of statins for primary prevention of atherosclerotic cardiovascular disease among people living with HIV in the United States.Journal of the International AIDS Society 2021;
24:e25690.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33749164>
12. Özdener-Poyraz AE, Vaidean G.Preventive Cardiovascular Care in Patients With HIV Infection in an Outpatient Clinic.Journal of pharmacy

practice 2021:8971900211000700.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33736523>

13. Giannis D, Barish MA, Goldin Met *al*. Incidence of Venous Thromboembolism and Mortality in Patients with Initial Presentation of COVID-19. Journal of thrombosis and thrombolysis 2021:1-5.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33665766>
14. Lima Cunha D, Richardson R, Tracey-White Det *al*. REP1-deficiency causes systemic dysfunction of lipid metabolism and oxidative stress in choroideremia. JCI insight 2021.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33755601>
15. Yetmar ZA, Challener DW, Tleyjeh IMet *al*. Association between Chronic Statin Use and 30-Day Mortality in Hospitalized Patients with COVID-19. Mayo Clinic proceedings. Innovations, quality & outcomes 2021.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33748678>
16. Zuin M, Rigatelli G, Bilato Cet *al*. Statin therapy is associated with less ICU admissions in COVID-19 patients. A preliminary analysis of the current observations. Minerva anestesologica 2021.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33688701>
17. Allan S, Olaiya R, Burhan R. Reviewing the use and quality of machine learning in developing clinical prediction models for cardiovascular disease. Postgraduate medical journal 2021.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33692158>
18. Sharma T, Abohashrh M, Baig MHet *al*. Screening of drug databank against WT and mutant main protease of SARS-CoV-2: Towards finding potential compound for repurposing against COVID-19. Saudi journal of biological sciences 2021.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33649700>
19. Moorman AJ, Dean LS, Yang E, Drezner JA. Cardiovascular Risk Assessment in the Older Athlete. Sports Health 2021:19417381211004877.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33733939>

PAD and statins

1. Jung KS, Heo SH, Woo SY *et al.* Factors associated with long-term graft patency after lower extremity arterial bypasses. Ann Surg Treat Res 2021; 100:175-185. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33748031>
2. Lecumberri E, Ruiz-Carmona C, Mateos E *et al.* Prognostic Value of Inflammatory Biomarkers in 5-Year Survival After Endovascular Repair of Abdominal Aortic Aneurysms in a Predominantly Male Cohort: Implications for Practice. World journal of surgery 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33721070>

Pleiotropic effects of statins

1. Liu P, Gao Q, Guan L *et al.* Atorvastatin attenuates surgery-induced BBB disruption and cognitive impairment partly by suppressing NF- κ B pathway and NLRP3 inflammasome activation in aged mice. Acta biochimica et biophysica Sinica 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33674828>
2. Yazdani Ashtiani S, Ahmad Nasrollahi S, Naeimifar A *et al.* Preparation and Safety Evaluation of Topical Simvastatin Loaded NLCs for Vitiligo. Advanced pharmaceutical bulletin 2021; 11:104-110. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33747857>
3. Chacko SR, DeJoy R, 3rd, Lo KB *et al.* Association of pre-admission statin use with reduced in-hospital mortality in COVID-19. Am J Med Sci 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33667433>
4. Du X, Li D, Wang G *et al.* Chemoprotective effect of atorvastatin against benzo(a)pyrene-induced lung cancer via the inhibition of oxidative stress and inflammatory parameters. Annals of translational medicine 2021; 9:355. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33708982>
5. Furtado RHM, Genestreti PR, Dalçóquio TF *et al.* Association between Statin Therapy and Lower Incidence of Hyperglycemia in Patients Hospitalized with Acute Coronary Syndromes. Arquivos brasileiros de cardiologia 2021; 116:285-294. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33656078>
6. Dai B, Li X, Xu J *et al.* Synergistic effects of magnesium ions and simvastatin on attenuation of high-fat diet-induced bone loss. Bioact Mater 2021; 6:2511-2522. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33665494>
7. Kauerova S, Bartuskova H, Muffova B *et al.* Statins Directly Influence the Polarization of Adipose Tissue Macrophages: A Role in Chronic

Inflammation.**Biomedicines** 2021;

9.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33669779>

8. Rizo-Liendo A, Arberas-Jiménez I, Sifaoui *et al.*The type 2 statins, cerivastatin, rosuvastatin and pitavastatin eliminate *Naegleria fowleri* at low concentrations and by induction of programmed cell death (PCD).**Bioorganic chemistry** 2021;
110:104784.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33684715>
9. Sung S, Al-Karaghoul M, Kalainy *Set al.*A systematic review on pharmacokinetics, cardiovascular outcomes and safety profiles of statins in cirrhosis.**BMC gastroenterology** 2021;
21:120.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33726685>
10. Ouahoud S, Jacobs RJ, Peppelenbosch MP *et al.*Kinome-wide analysis of the effect of statins in colorectal cancer.**Br J Cancer** 2021.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33742146>
11. Yulian ED, Siregar NC, Bajuadji.Combination of Simvastatin and FAC Improves Response to Neoadjuvant Chemotherapy in Advanced Local Breast Cancer.**Cancer research and treatment : official journal of Korean Cancer Association** 2021.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33705623>
12. Joseph P, Glynn R, Lonn *Eet al.*Rosuvastatin for the prevention of venous thromboembolism: a pooled analysis of the HOPE-3 and JUPITER randomized controlled trials.**Cardiovascular research** 2021.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33705531>
13. Ikonopoulou MP, Lopez-Mancheño Y, Novelle M *Get al.*LXR stimulates a metabolic switch and reveals cholesterol homeostasis as a statin target in Tasmanian devil facial tumor disease.**Cell Rep** 2021;
34:108851.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33730574>
14. Tiemann J, Lindenkamp C, Plümers *Ret al.*Statins as a Therapeutic Approach for the Treatment of Pseudoxanthoma Elasticum Patients: Evaluation of the Spectrum Efficacy of Atorvastatin In Vitro.**Cells** 2021;
10.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33669724>
15. Kuba JO, Yu Y, Klauda JB.Estimating Localization of Various Statins within a POPC Bilayer.**Chemistry and physics of lipids** 2021:105074.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33676920>
16. Kessinger CW, Qi G, Hassan MZ *Oet al.*Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Imaging Predicts Vein Wall Scarring

and Statin Benefit in Murine Venous Thrombosis.Circulation. Cardiovascular imaging 2021;Circimaging120011898.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33724049>

17. Cruz R, Moraschini V, Calasans-Maia MD *et al.* Clinical efficacy of simvastatin gel combined with polypropylene membrane on the healing of extraction sockets: a triple-blind, randomized clinical trial.Clinical oral implants research 2021.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33715258>
18. Li L, Cui N, Hao T *et al.* Statins use and the prognosis of colorectal cancer: a meta-analysis.Clin Res Hepatol Gastroenterol 2021; 45:101588.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33662632>
19. Kaplan DE, Mehta R, Garcia-Tsao G *et al.* SACRED: Effect of simvastatin on hepatic decompensation and death in subjects with high-risk compensated cirrhosis: Statins and Cirrhosis: Reducing Events of Decompensation.Contemporary clinical trials 2021; 104:106367.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33771685>
20. Marrache MK, Rockey DC. Statins for treatment of chronic liver disease.Current opinion in gastroenterology 2021.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33654016>
21. Nicholson CJ, Wooster L, Sigursslid H *et al.* Estimating risk of mechanical ventilation and in-hospital mortality among adult COVID-19 patients admitted to Mass General Brigham: The VICE and DICE scores.EClinicalMedicine 2021; 33:100765.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33655204>
22. Su VY, Pan SW, Yen YF *et al.* Statin use and impact on tuberculosis risk.Expert Rev Anti Infect Ther 2021;1-6.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33641582>
23. Jia W, Bai T, Zeng J *et al.* Combined Administration of Metformin and Atorvastatin Attenuates Diabetic Cardiomyopathy by Inhibiting Inflammation, Apoptosis, and Oxidative Stress in Type 2 Diabetic Mice.Front Cell Dev Biol 2021; 9:634900.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33718370>
24. Wang Y, Li Q, Yuan Z *et al.* Statin Use and Benefits of Thyroid Function: A Retrospective Cohort Study.Frontiers in endocrinology 2021; 12:578909.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33737906>

25. Cárdenas-Jaén K, Vaillo-Rocamora A, Gracia Á *et al.* Simvastatin in the Prevention of Recurrent Pancreatitis: Design and Rationale of a Multicenter Triple-Blind Randomized Controlled Trial, the SIMBA Trial. Frontiers in medicine 2020; 7:494. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33644082>
26. Michael L, Caspar M, Alexander K *et al.* Major Depressive Disorder (MDD) and Antidepressant Medication Are Overrepresented in High-Dose Statin Treatment. Frontiers in medicine 2021; 8:608083. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33644093>
27. Li Y, Guo Y, Zhou M *et al.* Paradoxical effect of statin medication on depressive disorder in first-ever ischemic stroke patients: possible antidepressant-like effect prestroke and the opposite in continuous medication poststroke. International clinical psychopharmacology 2021; 36:147-153. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33724252>
28. Menze ET, Ezzat H, Shawky S *et al.* Simvastatin mitigates depressive-like behavior in ovariectomized rats: Possible role of NLRP3 inflammasome and estrogen receptors' modulation. Int Immunopharmacol 2021; 95:107582. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33774267>
29. Liebow M, Larson MC, Thompson CA *et al.* Aspirin and other nonsteroidal anti-inflammatory drugs, statins and risk of non-Hodgkin lymphoma. International journal of cancer. Journal international du cancer 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33644854>
30. Damkjær M, Håkansson K, Kallemsø T *et al.* Statins in High-Risk Chronic Obstructive Pulmonary Disease Outpatients: No Impact on Time to First Exacerbation and All-Cause Mortality - The STATUETTE Cohort Study. International journal of chronic obstructive pulmonary disease 2021; 16:579-589. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33707941>
31. Huang YJ, Kao S, Kao L *et al.* Association Between Statin Use and Exacerbation of Chronic Obstructive Pulmonary Disease Among Patients Receiving Corticosteroids. International journal of chronic obstructive pulmonary disease 2021; 16:591-602. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33716501>
32. Kwak SY, Park S, Kim H *et al.* Atorvastatin Inhibits Endothelial PAI-1-Mediated Monocyte Migration and Alleviates Radiation-Induced Enteropathy. Int J Mol Sci 2021; 22. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33673196>

33. Grune C, Zens C, Czapka A *et al.* Sustainable preparation of anti-inflammatory atorvastatin PLGA nanoparticles. Int J Pharm 2021:120404. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33647413>
34. Wang H, Wang T, Zhang Z *et al.* Simvastatin inhibits oral squamous cell carcinoma by targeting TMEM16A Ca(2+)-activated chloride channel. Journal of cancer research and clinical oncology 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33755783>
35. Cho HW, Song IA, Oh TK. Prior Statin Therapy and Mortality After Extracorporeal Membrane Oxygenation Therapy: A Retrospective, Population-Based, Cohort Study. Journal of cardiothoracic and vascular anesthesia 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33715948>
36. Nomani H, Mohammadpour AH, Reiner Z *et al.* Statin Therapy in Post-Operative Atrial Fibrillation: Focus on the Anti-Inflammatory Effects. J Cardiovasc Dev Dis 2021; 8. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33652637>
37. Fiedler L, Hallsson L, Tscharré M *et al.* Upstream Statin Therapy and Long-Term Recurrence of Atrial Fibrillation after Cardioversion: A Propensity-Matched Analysis. Journal of clinical medicine 2021; 10. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33671264>
38. Li Y, Zhang YX, Ning D *et al.* Simvastatin inhibits POVPC-mediated induction of endothelial to mesenchymal cell transition. Journal of lipid research 2021:100066. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33711324>
39. Giannis D, Barish MA, Goldin M *et al.* Incidence of Venous Thromboembolism and Mortality in Patients with Initial Presentation of COVID-19. Journal of thrombosis and thrombolysis 2021:1-5. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33665766>
40. Lee J, Hong EM, Jung JH *et al.* Atorvastatin Induces FXR and CYP7A1 Activation as a Result of the Sequential Action of PPAR γ /PGC-1 α /HNF-4 α in Hep3B Cells. Korean J Gastroenterol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33686046>
41. Ciardullo S, Perseghin G. Statin use is associated with lower prevalence of advanced liver fibrosis in patients with type 2 diabetes. Metabolism 2021:154752. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33716004>

42. Chen N, Ren R, Wei X *et al.* Thermoresponsive Hydrogel-Based Local Delivery of Simvastatin for the Treatment of Periodontitis. Molecular pharmaceutics 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33754729>
43. Mounier NM, Wahdan SA, Gad AM, Azab SS. Role of inflammatory, oxidative, and ER stress signaling in the neuroprotective effect of atorvastatin against doxorubicin-induced cognitive impairment in rats. Naunyn-Schmiedeberg's archives of pharmacology 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33755739>
44. Du RW, Bu WG. Simvastatin Prevents Neurodegeneration in the MPTP Mouse Model of Parkinson's Disease via Inhibition of A1 Reactive Astrocytes. Neuroimmunomodulation 2021:1-8. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33735898>
45. Masson W, Lobo M, Masson G *et al.* Statin use in patients with elevated serum hepatic transaminases at baseline: A meta-analysis. Nutrition, metabolism, and cardiovascular diseases : NMCD 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33715945>
46. Fan Q, Gong T, Zheng C *et al.* Statins repress hedgehog signaling in medulloblastoma with no bone toxicities. Oncogene 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33649536>
47. van Gemert Y, Kozijn AE, Pouwer M *et al.* Novel high-intensive cholesterol-lowering therapies do not ameliorate knee OA development in humanized dyslipidemic mice. Osteoarthritis and cartilage 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33722697>
48. Cerda A, Bortolin RH, Manriquez V *et al.* Effect of statins on lipid metabolism-related microRNA expression in HepG2 cells. Pharmacological reports : PR 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33721286>
49. van Boheemen L, Turk S, Beers-Tas M *et al.* Atorvastatin is unlikely to prevent rheumatoid arthritis in high risk individuals: results from the prematurely stopped STATins to Prevent Rheumatoid Arthritis (STAPRA) trial. RMD Open 2021; 7. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33685928>
50. Sharma T, Abohashrh M, Baig M *et al.* Screening of drug databank against WT and mutant main protease of SARS-CoV-2: Towards finding potential

compound for repurposing against COVID-19. Saudi journal of biological sciences 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33649700>

51. Li HX, Liang XY, Wu JH *et al.* Simvastatin attenuates acute lung injury by activation of A2B adenosine receptor. Toxicology and applied pharmacology 2021:115460. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33774062>

Primary Prevention

1. Brodney S, Valentine KD, Sepucha K *et al.* Patient Preference Distribution for Use of Statin Therapy. JAMA network open 2021; 4:e210661. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33720368>
2. Castioni J, Abolhassani N, Vollenweider P *et al.* Polypill eligibility and equivalent intake in a Swiss population-based study. Scientific reports 2021; 11:6880. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33767231>

Registry data

1. Chacko SR, DeJoy R, 3rd, Lo K *et al.* Association of pre-admission statin use with reduced in-hospital mortality in COVID-19. Am J Med Sci 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33667433>
2. Shutta R, Nakatani D, Sakata Y *et al.* Hydrophilic vs. Lipophilic Statins in Diabetic Patients - Comparison of Long-Term Outcomes After Acute Myocardial Infarction. Circ Rep 2020; 2:280-287. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33693242>
3. Mack DS, Hume AL, Tjia J, Lapane KL. National Trends in Statin Use among the United States Nursing Home Population (2011-2016). Drugs Aging 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33694105>
4. Wang Y, Li Q, Yuan Z *et al.* Statin Use and Benefits of Thyroid Function: A Retrospective Cohort Study. Frontiers in endocrinology 2021; 12:578909. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33737906>
5. Michael L, Caspar M, Alexander K *et al.* Major Depressive Disorder (MDD) and Antidepressant Medication Are Overrepresented in High-Dose Statin Treatment. Frontiers in medicine 2021; 8:608083. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33644093>
6. Arnesen KE, Phung AV, Randsborg K *et al.* Risk of Recurrent Coronary Events in Patients With Familial Hypercholesterolemia; A 10-Years Prospective

Study.Frontiers in pharmacology 2020;
11:560958.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33737874>

7. Damkjær M, Håkansson K, Kallemsøe T *et al.* Statins in High-Risk Chronic Obstructive Pulmonary Disease Outpatients: No Impact on Time to First Exacerbation and All-Cause Mortality - The STATUETTE Cohort Study.International journal of chronic obstructive pulmonary disease 2021; 16:579-589.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33707941>
8. Ip YMB, Au L, Chan YYA *et al.* EXPRESS: Evolving Ischemic Stroke Subtypes in 15 years: A hospital-based observational study.Int J Stroke 2021;17474930211005953.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33724087>
9. Johannesen CDL, Mortensen MB, Langsted A, Nordestgaard BG. Apolipoprotein B and Non-HDL Cholesterol Better Reflect Residual Risk Than LDL Cholesterol in Statin-Treated Patients.J Am Coll Cardiol 2021; 77:1439-1450.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33736827>
10. Cho HW, Song IA, Oh TK. Prior Statin Therapy and Mortality After Extracorporeal Membrane Oxygenation Therapy: A Retrospective, Population-Based, Cohort Study.Journal of cardiothoracic and vascular anesthesia 2021.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33715948>
11. Lohia P, Kapur S, Benjaram S, Mir T. Association between antecedent statin use and severe disease outcomes in COVID-19: A retrospective study with propensity score matching.J Clin Lipidol 2021.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33726984>
12. Fiedler L, Hallsson L, Tscharré M *et al.* Upstream Statin Therapy and Long-Term Recurrence of Atrial Fibrillation after Cardioversion: A Propensity-Matched Analysis.Journal of clinical medicine 2021; 10.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33671264>
13. Youens D, Doust J, Robinson S, Moorin R. Regularity and Continuity of GP Contacts and Use of Statins Amongst People at Risk of Cardiovascular Events.Journal of general internal medicine 2021.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33655384>
14. Chhibber A, Hansen S, Biskupiak J. Statin use and mortality in rheumatoid arthritis: an incident user cohort study.Journal of managed care & specialty pharmacy 2021; 27:296-305.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33645241>

15. Hernández-Muñoz JJ, Wong ES, Kamdar CR. Prevalence of statin utilization and adherence among privately insured subjects in the Commonwealth of Puerto Rico. Journal of managed care & specialty pharmacy 2021; 27:392-398. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33645248>
16. Figtree GA, Vernon ST, Hadziosmanovic Net *al*. Mortality in STEMI patients without standard modifiable risk factors: a sex-disaggregated analysis of SWEDEHEART registry data. Lancet 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33711294>
17. Ciardullo S, Perseghin G. Statin use is associated with lower prevalence of advanced liver fibrosis in patients with type 2 diabetes. Metabolism 2021:154752. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33716004>
18. Zuin M, Rigatelli G, Bilato Cet *al*. Statin therapy is associated with less ICU admissions in COVID-19 patients. A preliminary analysis of the current observations. Minerva anesthesiologica 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33688701>

Renal Disease

1. Yen CL, Fan PC, Lin MSet *al*. Fenofibrate Delays the Need for Dialysis and Reduces Cardiovascular Risk among Patients with Advanced CKD. J Clin Endocrinol Metab 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33677489>
2. Yan L, Jiaqiong L, Yue Get *al*. Atorvastatin protects against contrast-induced acute kidney injury via upregulation of endogenous hydrogen sulfide. Ren Fail 2020; 42:270-281. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33685337>
3. Baliga MM, Klawitter J, Christians Uet *al*. Metabolic profiling in children and young adults with autosomal dominant polycystic kidney disease. Scientific reports 2021; 11:6629. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33758231>

Reviews

1. Lindsley J. Guideline recommendations, clinical trial data, and new and emerging therapies. The American journal of managed care 2021; 27:S70-s75. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33710846>

2. Patel J. Managed care pharmacist updates for proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. The American journal of managed care 2021; 27:S76-s82. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33710847>
3. Shaw PB. Hyperlipidemia: effective disease management with a focus on PCSK9 inhibitors. The American journal of managed care 2021; 27:S63-s69. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33710845>
4. Jo SH, Han SH, Kim SH *et al.* Cardiovascular effects of omega-3 fatty acids: Hope or hype? Atherosclerosis 2021; 322:15-23. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33706079>
5. Sung S, Al-Karaghoul M, Kalainy Set *al.* A systematic review on pharmacokinetics, cardiovascular outcomes and safety profiles of statins in cirrhosis. BMC gastroenterology 2021; 21:120. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33726685>
6. Ruscica M, Ferri N, Santos R *et al.* Lipid Lowering Drugs: Present Status and Future Developments. Curr Atheroscler Rep 2021; 23:17. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33694108>
7. Bahiru E, Hsiao R, Phillipson D, Watson KE. Mechanisms and Treatment of Dyslipidemia in Diabetes. Current cardiology reports 2021; 23:26. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33655372>
8. Ali AH, Younis N, Abdallah Ret *al.* Lipid-Lowering Therapies for Atherosclerosis: Statins, Fibrates, Ezetimibe and PCSK9 monoclonal antibodies. Curr Med Chem 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33655822>
9. Marrache MK, Rockey DC. Statins for treatment of chronic liver disease. Current opinion in gastroenterology 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33654016>
10. Pulipati VP, Davidson MH. The clinical black, white, and gray lessons. Curr Opin Lipidol 2021; 32:151-156. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33651748>
11. Strandberg TE, Kivimäki M. Increased mortality risk associated with statins in the CORONADO study. Diabetes Metab 2021:101250. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33744398>

12. Donovan GK, Wilson DP. Ethical Dilemmas in Pediatric Lipidology. In: Endotext. Edited by: Feingold KR, Anawalt B, Boyce Aet *al.* South Dartmouth (MA):MDText.com, Inc.Copyright © 2000-2021,MDText.com, Inc.; 2000.
13. Nguyen H, Akamnonu I, Yang T.Bempedoic Acid: a cholesterol lowering agent with a novel mechanism of action.Expert Rev Clin Pharmacol 2021;1-7.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33691561>
14. Yanai H, Yoshida H.Secondary dyslipidemia: its treatments and association with atherosclerosis.Glob Health Med 2021; 3:15-23.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33688591>
15. Camerino GM, Tarantino N, Canfora Iet *al.*Statin-Induced Myopathy: Translational Studies from Preclinical to Clinical Evidence.Int J Mol Sci 2021; 22.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33669797>
16. Nurmohamed NS, Navar AM, Kastelein JJP.New and Emerging Therapies for Reduction of LDL-Cholesterol and Apolipoprotein B: JACC Focus Seminar 1/4.J Am Coll Cardiol 2021; 77:1564-1575.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33766264>
17. Wu P, Nelson SD, Zhao J et *al.*DDIWAS: High-throughput electronic health record-based screening of drug-drug interactions.J Am Med Inform Assoc 2021.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33712848>
18. Hennig M, Brandt A, Bautembach-Minkowska J et *al.*When do paediatric patients with familial hypercholesterolemia need statin therapy?().J Mother Child 2021; 21:43-50.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33751874>
19. Rau M, Köppel-Fürer K, Knechtle B.[Doctor, Do You Know Red Yeast Rice?].Praxis 2021; 110:207-220.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33726520>
20. Soška V.Early and concurrent therapy of dyslipidemia and hypertension: when to start it and how to maintain patient's good and long-term adherence?Vnitr Lek 2021; 67:37-40.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33752389>

Safety and side effects

1. Ni X, Yang ZZ, Ye LQ et *al.*Establishment of an in vitro safety assessment model for lipid-lowering drugs using same-origin human pluripotent stem

cell-derived cardiomyocytes and endothelial cells.Acta pharmacologica Sinica 2021.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33686244>

2. Alamer A, Te C, Fazel MT. Rosuvastatin Myotoxicity After Starting Canagliflozin Treatment.Annals of internal medicine 2021; 174:431.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33721529>
3. Brailovski E, Kim RB, Juurlink D. Rosuvastatin Myotoxicity After Starting Canagliflozin Treatment.Annals of internal medicine 2021; 174:432.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33721527>
4. Mamidi R, Devineni D, Sun Det *al.* Rosuvastatin Myotoxicity After Starting Canagliflozin Treatment.Annals of internal medicine 2021; 174:431-432.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33721528>
5. Adalsteinsson JA, Muzumdar S, Waldman Ret *al.* Statins are associated with increased risk of squamous cell carcinoma of the skin: a whole-population study from Iceland.Arch Dermatol Res 2021.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33772628>
6. Furtado RHM, Genestreti PR, Dalçóquio TF *et al.* Association between Statin Therapy and Lower Incidence of Hyperglycemia in Patients Hospitalized with Acute Coronary Syndromes.Arquivos brasileiros de cardiologia 2021; 116:285-294.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33656078>
7. Sung S, Al-Karaghoul M, Kalainy Set *al.* A systematic review on pharmacokinetics, cardiovascular outcomes and safety profiles of statins in cirrhosis.BMC gastroenterology 2021; 21:120.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33726685>
8. Webster P, Wiemer N, Al Harash Aet *al.* Challenges in Treating Statin-Associated Necrotizing Myopathy.Case Rep Rheumatol 2021; 2021:8810754.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33708450>
9. Kanagalingam T, Lazarte J, Wong DKH, Hegele RA. Liver Injury Associated With Ezetimibe Monotherapy.CJC Open 2021; 3:195-197.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33644733>
10. Hermann R, Gundlach K, Seiler D. Mechanistic Considerations About an Unexpected Ramipril Drug-Drug Interaction in the Development of a Triple Fixed-Dose Combination Product Containing Ramipril, Amlodipine, and Atorvastatin.Clinical pharmacology in drug development 2021.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33773093>

11. Huh KY, Lee SW, Lee SB *et al.* Pharmacokinetic Interaction Among Ezetimibe, Rosuvastatin, and Telmisartan. Clinical pharmacology in drug development 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33647189>
12. Albassam AA, Alanazi A, Alhaqbani Net *al.* The potential of drug-herbal interaction among patients with chronic diseases in Saudi Arabia. Complement Ther Clin Pract 2021; 43:101324. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33765548>
13. Kaplan DE, Mehta R, Garcia-Tsao Get *al.* SACRED: Effect of simvastatin on hepatic decompensation and death in subjects with high-risk compensated cirrhosis: Statins and Cirrhosis: Reducing Events of Decompensation. Contemporary clinical trials 2021; 104:106367. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33771685>
14. Boppana SH, Syed HA, Antwi-Amoabeng Det *al.* Atorvastatin-Induced Necrotizing Myopathy and its Response to Combination Therapy. Cureus 2021; 13:e12957. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33659112>
15. Silvano J, Marques N, Tavares I, Ferreira I. Severe L-asparaginase-induced Hypertriglyceridaemia Treated with Plasmapheresis. European journal of case reports in internal medicine 2021; 8:002342. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33768080>
16. Valladales-Restrepo LF, Medina-Morales DA, Giraldo-Giraldo C, Machado-Alba JE. Prescription of statins and pharmacokinetic interactions in Colombian patients. Expert Opin Drug Metab Toxicol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33759676>
17. Lei HP, Qin M, Cai LY *et al.* UGT1A1 rs4148323 A Allele is Associated With Increased 2-Hydroxy Atorvastatin Formation and Higher Death Risk in Chinese Patients With Coronary Artery Disease. Frontiers in pharmacology 2021; 12:586973. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33762934>
18. Herrett E, Williamson E, Brack Ket *al.* The effect of statins on muscle symptoms in primary care: the StatinWISE series of 200 N-of-1 RCTs. Health technology assessment (Winchester, England) 2021; 25:1-62. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33709907>

19. Camerino GM, Tarantino N, Canfora *let al.* Statin-Induced Myopathy: Translational Studies from Preclinical to Clinical Evidence. Int J Mol Sci 2021; 22.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33669797>
20. Ip YMB, Au L, Chan YYA *et al.* EXPRESS: Evolving Ischemic Stroke Subtypes in 15 years: A hospital-based observational study. Int J Stroke 2021:17474930211005953.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33724087>
21. Mueller AM, Liakoni E, Schneider *Cet al.* The Risk of Muscular Events Among New Users of Hydrophilic and Lipophilic Statins: an Observational Cohort Study. Journal of general internal medicine 2021.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33751411>
22. Masson W, Lobo M, Masson *Get al.* Statin use in patients with elevated serum hepatic transaminases at baseline: A meta-analysis. Nutrition, metabolism, and cardiovascular diseases : NMCD 2021.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33715945>

Stroke and CNS

1. Terman SW, Aubert CE, Hill CE *et al.* Cardiovascular disease risk, awareness, and treatment in people with epilepsy. Epilepsy & behavior : E&B 2021; 117:107878.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33690068>
2. Lu T, Yang X, Cai *Yet al.* Prestroke Statins Improve Prognosis of Atrial Fibrillation-Associated Stroke through Increasing Suppressor of Cytokine Signaling-3 Levels. European neurology 2021:1-7.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33684912>
3. Li Y, Guo Y, Zhou *Met al.* Paradoxical effect of statin medication on depressive disorder in first-ever ischemic stroke patients: possible antidepressant-like effect prestroke and the opposite in continuous medication poststroke. International clinical psychopharmacology 2021; 36:147-153.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33724252>
4. Sarfo FS, Adamu S, Obese *Vet al.* Atherosclerotic event risk and risk reduction therapies among Ghanaian hemorrhagic stroke survivors. J Neurol Sci 2021; 424:117389.<http://www.ncbi.nlm.nih.gov/pubmed/?term=33773409>
5. Du RW, Bu WG. Simvastatin Prevents Neurodegeneration in the MPTP Mouse Model of Parkinson's Disease via Inhibition of A1 Reactive

Astrocytes.Neuroimmunomodulation 2021:1-

8. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33735898>

- 6. Bai F, Chen J, Pandey Det al.Stroke Risk Factor Status and Use of Stroke Prevention Medications Among Hispanic/Latino Adults in HCHS/SOL.Stroke 2021:Strokeaha120031216.** <http://www.ncbi.nlm.nih.gov/pubmed/?term=33657859>

Triglycerides/HDL

- 1. Farooque U, Lohano AK, Dahri Qet al.The Pattern of Dyslipidemia in Chronic Liver Disease Patients.Cureus 2021;** **13:e13259.** <http://www.ncbi.nlm.nih.gov/pubmed/?term=33728198>
- 2. Silvano J, Marques N, Tavares I, Ferreira I.Severe L-asparaginase-induced Hypertriglyceridaemia Treated with Plasmapheresis.European journal of case reports in internal medicine 2021;** **8:002342.** <http://www.ncbi.nlm.nih.gov/pubmed/?term=33768080>
- 3. Bornfeldt KE.Triglyceride lowering by omega-3 fatty acids: a mechanism mediated by N-acyl taurines.J Clin Invest 2021;** **131.** <http://www.ncbi.nlm.nih.gov/pubmed/?term=33720044>
- 4. Brodney S, Valentine KD, Sepucha Ket al.Patient Preference Distribution for Use of Statin Therapy.JAMA network open 2021;** **4:e210661.** <http://www.ncbi.nlm.nih.gov/pubmed/?term=33720368>

Trials

- 1. Malik A, Ramadan A, Vemuri Bet al.ω-3 Ethyl ester results in better cognitive function at 12 and 30 months than control in cognitively healthy subjects with coronary artery disease: a secondary analysis of a randomized clinical trial.The American journal of clinical nutrition 2021.** <http://www.ncbi.nlm.nih.gov/pubmed/?term=33675344>
- 2. Furtado RHM, Genestreti PR, Dalçãoquio TFet al.Association between Statin Therapy and Lower Incidence of Hyperglycemia in Patients Hospitalized with Acute Coronary Syndromes.Arquivos brasileiros de cardiologia 2021;** **116:285-294.** <http://www.ncbi.nlm.nih.gov/pubmed/?term=33656078>
- 3. Nishikido T, Fayyad R, Melamed S, Ray KK.TRS2P and LDL-C alone or in combination for predicting absolute benefits from additional LDL-C**

lowering: Analysis from the TNT trial. Atherosclerosis 2021; 322:8-14. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33706084>

4. Yulian ED, Siregar NC, Bajuadji. Combination of Simvastatin and FAC Improves Response to Neoadjuvant Chemotherapy in Advanced Local Breast Cancer. Cancer research and treatment : official journal of Korean Cancer Association 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33705623>
5. Otake H, Tanimura K, Sugizaki *et al.* Effect of Alirocumab and Rosuvastatin or Rosuvastatin Alone on Lipid Core Plaque in Coronary Artery Disease Seen on Near-Infrared Spectroscopy Intravascular Ultrasound (ANTARES). Circ Rep 2019; 1:107-111. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33693121>
6. Strandberg TE, Kivimäki M. Increased mortality risk associated with statins in the CORONADO study. Diabetes Metab 2021:101250. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33744398>
7. Diaz R, Li QH, Bhatt D *et al.* Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial. Eur J Prev Cardiol 2021; 28:33-43. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33755145>
8. Cárdenas-Jaén K, Vaillo-Rocamora A, Gracia Á *et al.* Simvastatin in the Prevention of Recurrent Pancreatitis: Design and Rationale of a Multicenter Triple-Blind Randomized Controlled Trial, the SIMBA Trial. Frontiers in medicine 2020; 7:494. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33644082>
9. Herrett E, Williamson E, Brack *et al.* The effect of statins on muscle symptoms in primary care: the StatinWISE series of 200 N-of-1 RCTs. Health technology assessment (Winchester, England) 2021; 25:1-62. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33709907>
10. Nagayama D, Saiki A, Watanabe *et al.* Prevention of Cardiovascular Events with Pitavastatin is Associated with Increased Serum Lipoprotein Lipase Mass Level: Subgroup Analysis of the TOHO-LIP. J Atheroscler Thromb 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33642441>
11. Nomani H, Mohammadpour AH, Reiner Ž *et al.* Statin Therapy in Post-Operative Atrial Fibrillation: Focus on the Anti-Inflammatory Effects. J Cardiovasc Dev Dis 2021; 8. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33652637>

12. Tara S, Yamamoto T, Sakai Set *al.* Clinical characteristics, secondary prevention goal attainment, and outcomes of patients with recurrent acute coronary syndrome. *J Nippon Med Sch* 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33692293>
13. Oh M, Kim H, Shin EW *et al.* Statin/ezetimibe combination therapy vs statin monotherapy for carotid atherosclerotic plaque inflammation. *Medicine (Baltimore)* 2021; 100:e25114. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33725908>
14. van Boheemen L, Turk S, Beers-Tas M *et al.* Atorvastatin is unlikely to prevent rheumatoid arthritis in high risk individuals: results from the prematurely stopped STATins to Prevent Rheumatoid Arthritis (STAPRA) trial. *RMD Open* 2021; 7. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33685928>
15. Kao YC, Chen TH, Liu CH *et al.* Similar major cardiovascular outcomes between pure statin and ezetimibe-statin in comparable intensity for type 2 diabetes with extremely atherosclerotic risks. *Scientific reports* 2021; 11:6697. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33758291>

 [Twitter](#)

 [IAS Website](#)

 [For information](#)

You are now on the editors mailing list of the IAS Statin Newsletter.
The IAS Statin Newsletter is part of the IAS News and Literature update service.

This activity is supported by an educational grant from Viatrix.